Medical University of South Carolina
Charleston, South Carolina, 29412, United States
NCT Number: NCT01459692
Neurologically-impaired individuals may have significant neurologic morbidity related to epilepsy and seizure disorders. Finding safe, noninvasive methods of decreasing seizures, and potentially reversing the epileptogenic process, is of paramount importance in improving the lives of those with epilepsy.
Looking for future studies?
Notify Me5 year–90 year
All sexes
Interventional
Not applicable
Charleston, South Carolina, 29412, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
Time frame: 3 years
Main Outcome Measure: The effect of exposure to the auditory stimulus on seizure frequency. Changes in seizure rates from baseline to treatment years were determined and statistically compared within the treatment and control groups, as well as between the groups to assess efficacy of treatment.
Medical University of South Carolina
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06714448
Brain Diseases, Central Nervous System Diseases
Chilly-Mazarin, France
View Trial DetailsNCT04770337
Brain Diseases, Central Nervous System Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT04259125
Brain Diseases, Central Nervous System Diseases
Oakland, California, United States
View Trial DetailsNCT03369522
Brain Diseases, Central Nervous System Diseases
Béthune, France
View Trial Details